Compare · BEAT vs SYK
BEAT vs SYK
Side-by-side comparison of Heartbeam Inc. (BEAT) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEAT and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $113.09B, about 2288.0x BEAT ($49.4M).
- Over the past year, BEAT is down 46.5% and SYK is down 22.9% - SYK leads by 23.6 points.
- SYK has been more active in the news (10 items in the past 4 weeks vs 4 for BEAT).
- SYK has more recent analyst coverage (25 ratings vs 8 for BEAT).
- Company
- Heartbeam Inc.
- Stryker Corporation
- Price
- $0.90+4.42%
- $295.17+0.58%
- Market cap
- $49.4M
- $113.09B
- 1M return
- +5.16%
- +1.42%
- 1Y return
- -46.53%
- -22.90%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 4
- 10
- Recent ratings
- 8
- 25
Heartbeam Inc.
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest BEAT
- HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home
- SEC Form 10-Q filed by Heartbeam Inc.
- HeartBeam Reports First Quarter 2026 Results
- HeartBeam Initiates Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic
- HeartBeam Expands Commercial Presence Across Four Key U.S. Markets with Addition of Premier Concierge Practice
- TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
- HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time
- Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)
- HeartBeam downgraded by D. Boral Capital
- SEC Form 4 filed by Cruickshank Tim
Latest SYK
- President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)
- Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
- VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)
- Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)
- Stryker Launches Pangea Plating System and Completes First Case in Europe
- SEC Form SD filed by Stryker Corporation
- SEC Form 8-K filed by Stryker Corporation
- BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
- VP, Chief HR Officer Fink M Kathryn exercised 21,582 shares at a strike of $167.98, covered exercise/tax liability with 16,362 shares and sold $2,473,756 worth of shares (8,720 units at $283.69) (SEC Form 4)
- SEC Form 10-Q filed by Stryker Corporation